By Neng Nana 
In an era where healthcare is increasingly digital, the irony of the industry remains stark: the lifeblood of medicine—patient records—remains trapped in a fragmented, analog-heavy ecosystem. Today, xCures, an AI-powered health tech startup, announced it has secured $46 million in a Series B financing round, signaling a major vote of confidence from investors in the company’s mission to transform “dirty,” unstructured medical data into actionable clinical intelligence.
The round, led by Innovius Capital with participation from iGrow, Spring Mountain Capital, and a roster of existing backers, brings the company’s total funding to over $76 million since its inception in 2018. More notably, the financing values the company at $127 million post-money, a staggering leap that more than doubles its valuation from its $25 million Series A round in December 2023.
The Evolution: From Cancer Support to Data Infrastructure
To understand the trajectory of xCures, one must look at its origins. Founded as a spinout from Cancer Commons by Marty Tenenbaum, the company originally set out to provide decision-support tools for patients battling late-stage (Stage 3 and 4) recalcitrant cancers. The goal was noble: helping patients navigate clinical trials and treatment options when standard care had failed.
However, as the team worked with thousands of patients across the United States, they hit a wall that has stymied healthcare innovation for decades. "What we learned in the process was that the decision-making was hard," said Mika Newton, CEO of xCures, in an exclusive interview. "These are complicated things, but doable. But the even harder thing was to get our hands on the data and information about the patient that we needed in order to give them the advice in the first place."
In the early days, the company’s operations team was literally receiving patient records via fax machines and FedEx boxes. This logistical bottleneck was the catalyst for a fundamental pivot. Recognizing that the industry lacked a reliable way to synthesize scattered patient information, xCures shifted its focus toward building the underlying infrastructure to connect directly to national healthcare interoperability networks. Today, the company has evolved from a patient-facing service into a critical data layer for the healthcare industry, specializing in structuring the "dirty data" that haunts hospitals and diagnostic labs.
A Technical Deep Dive: The Clinical Clarity Engine
The core of the xCures value proposition lies in its proprietary "Clinical Clarity Engine." In the current healthcare landscape, patient records are dispersed across thousands of silos—labs, imaging centers, specialist offices, and disparate electronic health record (EHR) systems. When this data is aggregated, it is often duplicative, riddled with human-entry errors, and composed of unstructured narrative text, scans, and images.
While other players in the space act as data conduits—simply moving information from Point A to Point B—xCures focuses on transformation. By integrating with national electronic exchanges, the engine pulls this raw data and, through a combination of proprietary machine learning and frontier AI models, turns it into decision-ready clinical insights.
To date, the company has processed over 300 million medical records sourced from more than 550,000 healthcare locations nationwide. According to CEO Mika Newton, the engine is significantly ahead of market competitors, as it does not merely transport data but renders it "instantly useful" for clinicians and administrators.
Governance in the Age of AI
A primary concern for any AI-integrated healthcare tool is accuracy and bias. To manage this, xCures employs a sophisticated governance framework. Rather than relying on a single, expensive, and potentially prone-to-hallucination model, the company utilizes a "harness" approach. By combining home-grown machine learning models with various commercial AI vendors, xCures ensures that the tasks assigned to the AI are well-defined, appropriate, and subject to clear clinical rules of engagement. This multi-layered architecture allows the company to handle high volumes of data without the astronomical costs associated with running massive, unstructured files through generic Large Language Models (LLMs).
The Economic Implications: Breaking the Administrative Logjam
The administrative burden on the American healthcare system is arguably its most expensive drag. Between prior authorizations, medical necessity documentation, and insurance appeals, billions of dollars are wasted annually on manual labor.
xCures’ business model is built to tackle this directly. Operating on a usage-based SaaS model with committed caps, the startup has seen explosive growth. Revenue climbed from roughly $3 million in 2025 to $10 million in annualized recurring revenue (ARR) in the same period, with projections to surpass $20 million by 2026.
The company’s customer base has grown to 25 major enterprise clients, including industry heavyweights like Exact Sciences, Caris Life Sciences, and Novocure. The utility of the Clinical Clarity Engine is vast:
- Operating Room Management: Hospital networks use the tool to instantly generate patient histories, screen for comorbidities, and estimate operative times, significantly reducing scheduling inefficiencies.
- Telehealth: Providers lacking legacy EHR architectures use xCures to consolidate patient histories for remote diagnostics.
- Payer Efficiency: Medicare Advantage plans utilize the engine to automate population risk stratification and the labor-intensive process of prior authorizations.
Industry Context: The AI Health Tech Surge
xCures’ successful funding round is part of a broader, massive surge in venture capital flowing into AI-powered health tech. As of June 2025, investors had poured an estimated $8.5 billion into seed-to-growth stage startups in the sector. The total funding for 2025 across all stages reached $15.8 billion, nearly doubling the $8.6 billion invested in the entirety of 2024.
This environment suggests that investors are moving past the initial "hype" phase of AI and are now betting heavily on infrastructure companies that solve tangible, expensive operational problems.
"We backed xCures because they are solving the fundamental issue of location, extraction, and normalization," said Stu Posluns, a partner at Innovius Capital. "By applying real clinical context to surface exactly what matters, Mika and his team are building the foundational AI data layer that will power the entire healthcare industry."
Looking Ahead: The 2027 Pipeline
Despite reaching cash-flow breakeven in 2025, xCures has consciously moved into a period of aggressive capital burn. According to Newton, this is a strategic choice to scale the team and infrastructure required to support the company’s 2027 business pipeline.
The company’s vision is not to replace the doctor, but to eliminate the "grunt work" that distracts them from patient care. By automating the ingestion and interpretation of medical records, xCures is positioning itself as the "plumbing" of the future healthcare system—a silent, indispensable layer that makes the clinical workflow faster, cheaper, and more accurate.
For a system long characterized by its resistance to change and its reliance on antiquated systems like fax machines, xCures represents a shift toward a future where data works for the clinician, rather than the other way around. As the company prepares for its next phase of growth, the $46 million influx provides not just runway, but the necessary resources to ensure that the promise of AI in medicine finally matches the reality of clinical practice.
Sagoh 
Azzam Bilal Chamdy 
Pevita Pearce 